Evommune EVMN
NYSE EVMN
$8.64 +0.80 (+10.14%)
As of: Nov 11, 2026 · 3:59 PM EST

Evommune (EVMN) Net Equity Issued and Repurchased (2024 - 2026)

Updated

Evommune (EVMN) posted Net Equity Issued and Repurchased of $674,000 for Q2 2026, compared with $4,000 a year earlier and down 99.4% from the prior quarter.

Analysis

Evommune (EVMN) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Net Equity Issued and Repurchased at Evommune was $275.16 million; for FY2025, it came in at $222.52 million, up 346.4% from FY2024.

  • In prior years, Evommune's Net Equity Issued and Repurchased was $49.84 million in FY2024.
  • Quarterly Net Equity Issued and Repurchased has run from a low of $2,000 in Q1 2025 to a high of $157.28 million in Q4 2025 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -377.00 Mn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -966.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -5.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -406.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 4.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -283.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Evommune 285.17 Mn -352.34 Mn - 674,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 674,000.00
Mar 31, 2026 117.20 Mn
Dec 31, 2025 157.28 Mn
Jun 30, 2025 4,000.00
Mar 31, 2025 2,000.00
Dec 31, 2024 11,000.00
API Access

Evommune Net Equity Issued and Repurchased API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-equity-issued-and-repurchased&ticker=EVMN&period=max&api_key=YOUR_API_KEY